Open AccessInterim fluoro-2-deoxy-D-glucose–PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection
Author(s) -
Jessica Okosun,
V. Warbey,
Kate Shaw,
Silvia Montoto,
Paul Fields,
Robert Marcus,
Andres Virchis,
Christopher McNamara,
Mark Bower,
Kate Cwynarski
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32835213b1
Subject(s) - abvd , medicine , interim , dacarbazine , vinblastine , lymphoma , progression free survival , bleomycin , oncology , chemotherapy , nuclear medicine , vincristine , cyclophosphamide , archaeology , history
Interim PET scans in HIV-negative patients with Hodgkin lymphoma has emerged as one of the most important prognostic tools. However, equivalent studies in HIV-positive patients are yet to be performed.